Vaxart to Present at ASM Microbe 2019
June 20 2019 - 8:00AM
Business Wire
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology
company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced that Roberto
Mateo, Ph.D., senior scientist at Vaxart, will present preclinical
results of its oral Respiratory Syncytial Virus (RSV) vaccine in a
poster presentation at the American Society of Microbiology 2019,
taking place from June 20-24, 2019 in San Francisco,
California.
Details of the presentation are as follows:
Poster Title:
Oral Adenovirus-Based Vaccine Induces
Respiratory MucosalMemory and Protection against Respiratory
Syncytial VirusInfection in Cotton Rats
Date & Time:
Saturday, June 22, 2019 from 10:30 AM – 5:00 PM PST
Authors:
Roberto Mateo, et al.
Session:
SATURDAY- CIV Late-breakers
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on
developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed
to generate broad and durable immune responses that protect against
a wide range of infectious diseases and may also be useful for the
treatment of chronic viral infections and cancer. Vaxart’s vaccines
are administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tablet
vaccines are easier to distribute and administer than injectable
vaccines and have the potential to significantly increase
vaccination rates. Vaxart’s development programs include oral
tablet vaccines that are designed to protect against norovirus,
seasonal influenza and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV).
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our strategy, prospects, plans and objectives, results
from preclinical and clinical trials, commercialization agreements
and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “believe,” “could,” “potential,”
“will” and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to the Vaxart’s ability to develop and commercialize its
product candidates and clinical results and trial data; the
expected timing of the initiation of the Phase 1 bivalent study and
Phase 2 monovalent challenge study; and Vaxart’s expectations with
respect to the important advantages it believes its oral vaccine
platform can offer over injectable alternatives, particularly for
mucosal pathogens such as norovirus, flu and
RSV. Vaxart may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
our forward-looking statements and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially from the forward-looking statements
that Vaxart makes, that Vaxart’s product candidates may
not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or
non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; that Vaxart may
experience manufacturing issues and delays; and other risks
described in the “Risk Factors” sections of Vaxart’s Quarterly and
Annual Reports filed with the SEC. Vaxart does not
assume any obligation to update any forward-looking statements,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190620005007/en/
Daniella FunaroStern Investor
Relations212-362-1200vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024